In light of the multiple ways by which Pi3K-AKT-mTOR pathway activation impacts meningioma biology, we analyzed here for the first time the effect of the Pi3K inhibitor alpelisib and compared its effect with that one of the mTOR inhibitor, everolimus, commonly used today to treat aggressive meningioma. This evidence concerns the gene PIK3CA and meningioma.